Navigation Links
Abbott to Present New Data Across its Vascular Portfolio at the,,,American College of Cardiology's 56th Annual Scientific Session

Highlights Include First U.S. Clinical Data on XIENCE V Everolimus Eluting Coronary Stent System and Six-Month Patient Follow-Up Results from the ABSORB Bioabsorbable Stent Clinical Study

ABBOTT PARK, Ill., March 19, 2007 /PRNewswire-FirstCall/ -- Abbott will present data from several studies across its broad vascular portfolio and pipeline during a number of late-breaking clinical trial and poster sessions at the of Cardiology's 56th Annual Scientific Session being held March 24-27 in New Orleans at the Ernest N. Morial Convention Center.

Late-breaking data presentations from Abbott will include the first U.S. clinical data results from the SPIRIT III pivotal clinical trial comparing the performance at nine months of the XIENCE(TM) V Everolimus Eluting Coronary Stent System to the TAXUS(R) Paclitaxel-Eluting Coronary Stent System; six- month data from ABSORB, the world's first clinical trial of a fully bioabsorbable drug-eluting stent; and interim 30-day data from two studies designed to confirm that carotid stenting can be performed with good results by a variety of physician specialties in real-world (non-clinical trial) settings in patients who are at high risk for carotid artery surgery. In addition, one-year follow-up data on patients enrolled in the SPIRIT II clinical trial will be presented during a poster session.

SPIRIT III Nine-Month Pivotal Clinical Data Results

Late-Breaking Clinical Trials I, i2. Summit Interventional Programming Saturday, March 24, 11:30 a.m. Central Time

Room La Nouvelle Orleans C, Ernest N. Morial Convention Center

Gregg W. Stone, M.D., of Medical Center and the Cardiovascular Research Foundation, New York, will present results from the randomized portion of Abbott's SPIRIT III pivotal clinical trial. SPIRIT III is a large-scale U.S. trial designed to compare Abbott's XIENCE V Evero limus Eluting Coronary Stent System with Boston Scientific's TAXUS Paclitaxel- Eluting Coronary Stent System. The primary endpoint of the trial is in-segment late loss at 240 days. The major secondary endpoint of the randomized portion of the trial is ischemia driven target vessel failure at 270 days. The results from SPIRIT III are intended to support approval of the XIENCE V Stent System by the U.S. Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare.

ABSORB: Bioabsorbable Clinical Trial Six-Month Data Results

Late-Breaking Clinical Trials I, i2. Summit Interventional Programming Saturday, March 24, 11 a.m. Central Time

Room La Nouvelle Orleans C, Ernest N. Morial Convention Center

Abbott's ABSORB study is the world's first clinical trial designed to evaluate the safety and performance of a fully bioabsorbable everolimus- eluting coronary stent platform. Patrick W. Serruys, M.D., Ph.D., of the Thoraxcentre, Erasmus University Hospital, Rotterdam, will present six-month clinical and angiographic results from the first 30 patients enrolled in the study.

Late-Breaking Clinical Trials I Press Conference at ACC

SPIRIT III data and ABSORB results will be included in the ACC late- breaking trials press conference I being held at noon Central time on Saturday, March 24, in Press Conference Room 215.

Abbott Investor Meeting and Webcast

Saturday, March 24, 1:30 p.m. Central Time

Abbott will host an investor meeting on Saturday, March 24, at 1:30 p.m. Central time to review the results of its Xience V SPIRIT and ABSORB bioabsorbable stent clinical trials. A live audio webcast of the meeting will be accessible through Abbott's Investor Relations Web site at www.abbottinvestor.com. An archived edition of the presentation will be available later that day.

EXACT and CAPTURE 2 Carotid Clinical Trial 30-Day Results

Late-Breaking Clinical Trials III, i2. Summit Interventional Programming Monday, March 26, 11:15 a.m. Central Time

Room La Nouvelle Orleans C, Ernest N. Morial Convention Center

Interim results of 30-day clinical follow-up for the first 1,500 patients enrolled in Abbott's EXACT clinical study and the first 600 patients enrolled in CAPTURE 2 will be presented by William A. Gray, M.D., FACC, from the Medical Center in New York. EXACT and CAPTURE 2 are studies designed to confirm that carotid stenting can be performed with good results by a variety of physician specialties in real-world (non-clinical trial) settings in patients who are at high risk for carotid artery surgery. Clinical outcome data for Abbott's Emboshield BareWire(TM) Rapid Exchange Embolic Protection System and Xact Rapid Exchange Carotid Stent System and ACCULINK(TM) Carotid Stent System and ACCUNET(TM) Embolic Protection System will be reported.

Late-Breaking Clinical Trials III Press Conference at ACC

EXACT and CAPTURE 2 data will be included in the ACC late-breaking clinical trials III press conference at noon Central time on Monday, March 26, in Press Conference Room 215.

SPIRIT II One Year Clinical Results with 300 Patients

e-Poster Session 210 - Monday, March 26, 2 p.m. Central Time

Hall H, Ernest N. Morial Convention Center

One-year follow-up results from 300 patients in the SPIRIT II clinical trial will be presented in a poster session by Peter Ruygrok, M.D., cardiologist at Auckland City Hospital and Clinical Associate Professor at University of Auckland, New Zealand. This is the first time that long-term data will be presented from SPIRIT II, a 300-patient, randomized, single- blind, prospective clinical trial evaluating XIENCE V versus TAXUS in Europe and Asia Pacific. In addition, Abbott will also pres ent one-year safety results reflecting the new Academic Research Consortium (ARC) definition of late-stent thrombosis, which was developed to eliminate variability in the definitions across various drug-eluting stent trials. Results of the SPIRIT II trial will provide additional clinical data to support the use of XIENCE V in countries outside the United States.

About Abbott Vascular

Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.

About Abbott

Abbott is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.

Abbott's news releases and other information are available on the company's Web site at www.abbott.com.

CONTACT: Media, Karin Bauer Aranaz, +1-415-859-3414, Nicole Osmer,+1-650-454-0504, or Financial, Tina Ventura, +1-847-935-9390

Web site: www.abbott.com

Ticker Symbol: (NYSE:ABT)

Terms and conditions of use apply
Copyright 2007 PR Newswire Association LLC. All rights reserved.
A United Bus iness Media Company


'"/>




Related medicine technology :

1. Three Studies Suggest Abbotts Humira (adalimumab) May Improve Work Productivity in Patients with Rheumatoid Arthritis
2. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
3. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
4. New Analysis of Data Shows Treatment With Abbotts Humira (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohns Disease
5. Abbotts Investigational Treatment ABT-874 Shows Positive Results in Phase II Psoriasis Study
6. Abbott Researchers Focus on New Cutting-Edge Approaches in the Fight Against Cancer
7. Two Abbott Studies Reaffirm Carotid Artery Stenting as a Safe and Effective Treatment to Reduce Risk of Stroke
8. Abbott Announces Positive Six-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug-Eluting Coronary Stent
9. Abbotts Xience V Everolimus Eluting Coronary Stent Superior to Taxus Stent in Spirit III U.S. Pivotal Clinical Trial
10. The Past, Present and Future of HLA Typing
11. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... , May 23, 2016 ... Devices, Diagnostics and Monitoring, and Vision Care ... Which areas are going to grow at the fastest ... revenues to 2026, assessing data, trends, opportunities and prospects. ... charts, and graphs. Discover the most lucrative areas in ...
(Date:5/23/2016)... , May 23, 2016 The ... USD 5.0 billion by 2022, according to a new ... of medical waste coupled with the lack of centralized ... expected to drive the demand for reprocessed medical devices ... as compared to that of the original device is ...
(Date:5/20/2016)... LONDON , May 20, 2016 ... for Therapeutic Antibody Technologies, Insulins, Growth Hormones, Recombinant ... Emerging Biological Drugs - This New Study Reveals ... Stay Ahead ,What is the ... get the latest technological and commercial analysis. Staying ...
Breaking Medicine Technology:
(Date:5/25/2016)... ... 25, 2016 , ... HealthPostures , a national ergonomics ... engineers at the American Society of Safety Engineers Conference in Atlanta, Georgia. The ... Engineers, speakers and exhibitors from more than 40 countries are scheduled to appear ...
(Date:5/24/2016)... ... May 24, 2016 , ... Sterling Global Products is ... unique and patented refillable hanging wipe dispenser. The campaign kick-off video is located via ... end June 25, 2016. The goal is to raise $1,000 per day for a ...
(Date:5/24/2016)... ... May 24, 2016 , ... Fire Door ... provide one resource, from start to finish, for Life Safety compliance. These ... Condition surveys requested by the Joint Commission, and fire stopping reviews, inspections, and ...
(Date:5/24/2016)... ... May 24, 2016 , ... United Benefit Advisors (UBA), ... Partner Firm Austin & Co., Inc. Headquartered in Albany, New York, Austin ... consulting, benefits technology, and beyond. As an employee-owned company celebrating over 160 ...
(Date:5/24/2016)... VA (PRWEB) , ... May 24, 2016 , ... How ... 2016 · Raleigh, NC, http://www.fdanews.com/humanerrordrugdevice , Human error is known to be ... unlikely that human error will ever be totally eliminated, many human performance problems can ...
Breaking Medicine News(10 mins):